title: Testing for ovarian cancer.
abstract: Ovarian cancer is responsible for more deaths per annum than cervical and endometrial cancer combined. Patients are often diagnosed at a late stage because of the non-specific symptoms of this disease. It can be difficult to differentiate between benign and malignant ovarian pathology, and a malignancy risk index has been developed to guide clinicians. The accuracy of CA125 and ultrasound scans as screening tests is being assessed in randomised controlled trials and proteomic technology shows promise for the early detection of cancers. At present, without accurate screening and early diagnostic techniques, high-risk patients often chose to have prophylactic surgery.
authors.affiliation: Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TT, UK. charlie.chan@bwhct.nhs.uk
authors.forename: K K
authors.initials: KK
authors.lastname: Chan
authors.forename: T J
authors.initials: TJ
authors.lastname: Selman
mesh_terms: D002277:Carcinoma / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D018570:Risk Assessment / Q000379:methods; D012680:Sensitivity and Specificity; D006113:United Kingdom / Q000453:epidemiology